Pars plana vitrectomy in the management of patients diagnosed with endophthalmitis following intravitreal anti-vascular endothelial growth factor injection

Retina

Volumn 33, Issue 7, 2013, Pages 1407-1416

  Chaudhary, Khurram M ^a   Romero, Juan M ^a,b   Ezon, Isaac ^a   Fastenberg, David M ^a,b   Deramo, Vincent A ^a,b  

^a North Shore Long Island Jewish Department of Ophthalmology   (United States)

^b Long Island Vitreoretinal Consultants   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

AGED; ARTICLE; CILIARY DISK; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; MALE; MEDICAL RECORD REVIEW; VISUAL ACUITY; VITRECTOMY; ANTAGONISTS AND INHIBITORS; EYE INFECTIONS, BACTERIAL; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITRECTOMY;

EID: 84879901760     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3182807659     Document Type: Article

References (23)

1. Wykoff CC, Houston SK, Berrocal AM. Anti-vascular endothelial growth factor agents for pediatric retinal diseases. Intern Ophthalmol Clin 2011;51:185-199.
2. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994;145:574-584.
3. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascities fluid. Science. 1983;219:983-985.
4. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
5. Schouten JS, La Heij EC, Webers CA, et al. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009;247:1-11.
6. Sørensen TL, Kamp H. [Intravitreal ranibizumab for agerelated macular degeneration]. Ugeskr Laeger 2010;172: 1685-1689.
7. Pieramici DJ, Avery RL. Ranibizumab: treatment in patients with neovascular age-related macular degeneration. Expert Opin Biol Ther 2006;6:1237-1245. Review.
8. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
9. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1431-1444.
10. Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008;92: 1606-1611.
11. Harder BC, Baltz SV, Jonas JB, Schlichtenbrede FC. Intravitreal bevacizumab for retinopathy of prematurity. J Ocul Pharmacol Ther 2011:27:623-627.
12. Shah CP, Garg SJ, Vander JF, et al. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology 2011:118:2028-2034.
13. Klein KS, Walsh MK, Hassan TS, et al. Endophthalmitis after anti-VEGF injections [letter]. Ophthalmology 2009;116:1225.
14. Diago T, McCannel CA, Bakri SJ, et al. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina 2009;29:601-605.
15. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in and office setting. Am J Ophthalmol 2008;145:879-882.
16. Endophthalmitis Vitrectomy Study Group. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995;113:1479-1496.
17. Brown DM, Kaiser PK, Michels M, et al. Ranibzumab versus vertoporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
18. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355;1419-1431.
19. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28:1395-1399.
20. Fong DS, Custis P, Howes J, Hsu JW. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration: a multicenter retrospective study. Ophthalmology 2010;30:485-490.
21. CATT Research Group, Martin DF,Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
22. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, et al. Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center. Retina 2011;31:662-668.
23. Mezad-Koursh D, Goldstein M, Heilwail G, et al. Clinical characteristics of endophthalmitits after an injection of intravitreal antivascular endothelial growth factor. Retina 2010;30: 1051-1057.